Skip to content
value.today

Arisaph Pharmaceuticals Inc.

Total raised
$10 M
1 round on record
Latest round
$10 M
Oct 2013
First round on record
Oct 2013
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Arisaph Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2013$10 MNo. 1$10 to $50 million

Arisaph Pharmaceuticals Inc.: Raise no. 1, Oct 2013

Investors in this round

1 investor had bought by the notice of Nov 1, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $20 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Kiritsy · Executive Officer, Director
  • Claude Benedict · Executive Officer
  • Joseph Suarez · Executive Officer
  • William Bachovchin · Executive Officer, Director
  • Antonio Gotto · Director
  • Kevin Ferro · Director
  • Madias Nicolaos · Director
  • Michael Jaharis · Director
  • Rex Roten · Director
  • Robert Baldini · Director
  • Steven Jaharis · Director
  • Thomas Koestler · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher Kiritsy, President. Source: SEC Form D, newest notice filed Nov 1, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Arisaph Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2013).

    SEC Form D · Nov 2013

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2013

That is all the official record says: Arisaph Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Arisaph Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 1 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Arisaph Pharmaceuticals Inc.
NameRoleNamed in
Christopher KiritsyExecutive officerNov 2013
Claude BenedictExecutive officerNov 2013
Joseph SuarezExecutive officerNov 2013
William BachovchinExecutive officerNov 2013
Antonio GottoDirectorNov 2013
Christopher KiritsyDirectorNov 2013
Kevin FerroDirectorNov 2013
Madias NicolaosDirectorNov 2013
Michael JaharisDirectorNov 2013
Rex RotenDirectorNov 2013
Robert BaldiniDirectorNov 2013
Steven JaharisDirectorNov 2013
Thomas KoestlerDirectorNov 2013
William BachovchinDirectorNov 2013